Treatment patterns and visual acuity change of AMD patients, before, during and after the COVID ‐19 pandemic lockdowns: A large cohort
Acta Ophthalmologica · 2024
DOI: 10.1111/aos.15756 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Acta Ophthalmologica, 2024. Verfasst von Dana Barequet und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: COVID-19, Wet Macular Degeneration. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the impact of the changes in treatment patterns before, during and after the COVID‐19 pandemic on best‐corrected visual acuity (BCVA) in previously treated neovascular age‐related macular degeneration (nAMD) patients.
Methods
A multi‐centre, retrospective, observational study of consecutive nAMD patients during 2019–2021. Data collected included demographics, BCVA, dates of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) injections and clinic visits.
Results
A total of 1652 eyes of 1652 nAMD patients were included, out of which 850 eyes were assessed in 2019 (pre‐COVID‐19), 630 eyes were assessed in 2020 (COVID‐19) and 974 eyes were assessed in 2021 (post‐COVID‐19). During the COVID‐19 period, the mean number of anti‐VEGF injections was significantly lower than the corresponding pre‐COVID‐19 and post‐COVID‐19 periods (5.55 compared to 6.13 and 6.60, respectively p < 0.01). A constant lower ratio of injections per patient/month was observed during COVID‐19 compared to previous and following years, with a notable decline during March–April, reaching a ratio of 0.4 in 2020 versus 0.65 in 2019 and 0.62 in 2021 ( p < 0.01). Baseline BCVA (0.825, p < 0.001), number of injections (−0.007, p < 0.001), gender (−0.027, p = 0.037) and age (0.004, p < 0.001) were shown to be significant predictors of final BCVA.
Conclusion
During the COVID‐19 period, patients were treated with significantly less intravitreal anti‐VEGF injection compared to the previous year with compensation in the following year. These changes in treatment patterns did not have a significant impact on BCVA outcomes. Age, gender, baseline BCVA and number of injections are predictors of final visual outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Ophthalmology, Meir Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Kfar Saba, Israel.
ORCID-Profile: Dana Barequet, Gilad Rabina
Zitieren
APA
Barequet, D., Shor, R., Segal, O., Greenbaum, E., Trivizki, O., Loewenstein, A., & Rabina, G. (2024). Treatment patterns and visual acuity change of AMD patients, before, during and after the COVID ‐19 pandemic lockdowns: A large cohort. Acta Ophthalmologica. https://doi.org/10.1111/aos.15756
Vancouver
Barequet D, Shor R, Segal O, Greenbaum E, Trivizki O, Loewenstein A, et al. Treatment patterns and visual acuity change of AMD patients, before, during and after the COVID ‐19 pandemic lockdowns: A large cohort. Acta Ophthalmologica. 2024. doi:10.1111/aos.15756
BibTeX
@article{Barequet2024,
author = {Barequet, Dana and Shor, Reut and Segal, Ori and Greenbaum, Eran and Trivizki, Omer and Loewenstein, Anat and Rabina, Gilad},
title = {Treatment patterns and visual acuity change of AMD patients, before, during and after the COVID ‐19 pandemic lockdowns: A large cohort},
journal = {Acta Ophthalmologica},
year = {2024},
doi = {10.1111/aos.15756}
}
EUVIMED